Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Pieters

Showing results (301-310 of 336) with videos related to

Pageof 34
Sort By:
Haematologica|August 13, 2013
Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international studyMarjolein Blink, Martin Zimmermann, Christine von Neuhoff, et al.
Haematologica|December 8, 2010
Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemiaIris H I M Hollink, Marry M van den Heuvel-Eibrink, Susan T C J M Arentsen-Peters, et al.
Blood|June 5, 2009
WT1 mutations in T-ALLValeria Tosello, Marc R Mansour, Kelly Barnes, et al.
Blood|August 5, 2011
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression patternIris H I M Hollink, Marry M van den Heuvel-Eibrink, Susan T C J M Arentsen-Peters, et al.
Blood|June 30, 2021
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno ConsortiumSwantje Buchmann, Martin Schrappe, Andre Baruchel, et al.
Nature Genetics|September 6, 2011
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemiaPriscila P Zenatti, Daniel Ribeiro, Wenqing Li, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
The Lancet. Oncology|January 14, 2009
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyMonique L Den Boer, Marjon van Slegtenhorst, Renée X De Menezes, et al.
Cancer Investigation|February 17, 2022
Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER CohortEllen Kilsdonk, Eline van Dulmen-den Broeder, Flora E van Leeuwen, et al.
Blood Advances|February 8, 2022
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemiaLinde Dekker, Friso G Calkoen, Yilin Jiang, et al.
Pageof 34

Showing results (301-310 of 336) with videos related to

Sort By:
Pageof 34
Haematologica|August 13, 2013
Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international studyMarjolein Blink, Martin Zimmermann, Christine von Neuhoff, et al.
Haematologica|December 8, 2010
Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemiaIris H I M Hollink, Marry M van den Heuvel-Eibrink, Susan T C J M Arentsen-Peters, et al.
Blood|June 5, 2009
WT1 mutations in T-ALLValeria Tosello, Marc R Mansour, Kelly Barnes, et al.
Blood|August 5, 2011
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression patternIris H I M Hollink, Marry M van den Heuvel-Eibrink, Susan T C J M Arentsen-Peters, et al.
Blood|June 30, 2021
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno ConsortiumSwantje Buchmann, Martin Schrappe, Andre Baruchel, et al.
Nature Genetics|September 6, 2011
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemiaPriscila P Zenatti, Daniel Ribeiro, Wenqing Li, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
The Lancet. Oncology|January 14, 2009
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyMonique L Den Boer, Marjon van Slegtenhorst, Renée X De Menezes, et al.
Cancer Investigation|February 17, 2022
Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER CohortEllen Kilsdonk, Eline van Dulmen-den Broeder, Flora E van Leeuwen, et al.
Blood Advances|February 8, 2022
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemiaLinde Dekker, Friso G Calkoen, Yilin Jiang, et al.
Pageof 34